| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | JANX | Common Stock | Sale | -$2.99M | -60.2K | -2.13% | $49.69 | 2.76M | Oct 16, 2024 | Direct | F1, F2 |
| transaction | JANX | Common Stock | Sale | -$579K | -11.7K | -2.13% | $49.69 | 535K | Oct 16, 2024 | By Avalon BioVentures I, LP | F1, F3 |
| transaction | JANX | Common Stock | Sale | -$3.05M | -61.4K | -2.13% | $49.69 | 2.82M | Oct 16, 2024 | By Avalon BioVentures SPV I, L.P. | F1, F4 |
| transaction | JANX | Common Stock | Sale | -$1.49M | -29.5K | -1.07% | $50.61 | 2.73M | Oct 16, 2024 | Direct | F2, F5 |
| transaction | JANX | Common Stock | Sale | -$289K | -5.71K | -1.07% | $50.61 | 529K | Oct 16, 2024 | By Avalon BioVentures I, LP | F3, F5 |
| transaction | JANX | Common Stock | Sale | -$1.52M | -30.1K | -1.07% | $50.61 | 2.79M | Oct 16, 2024 | By Avalon BioVentures SPV I, LP | F4, F5 |
| transaction | JANX | Common Stock | Options Exercise | $84.5K | +4.97K | +72.14% | $17.00 | 11.9K | Oct 16, 2024 | Direct | F6 |
| transaction | JANX | Common Stock | Options Exercise | $22.2K | +2.07K | +17.46% | $10.73 | 13.9K | Oct 16, 2024 | Direct | F6 |
| transaction | JANX | Common Stock | Options Exercise | $27.4K | +2.07K | +14.87% | $13.22 | 16K | Oct 16, 2024 | Direct | F6 |
| transaction | JANX | Common Stock | Options Exercise | $56K | +1.41K | +8.8% | $39.80 | 17.4K | Oct 16, 2024 | Direct | F6 |
| transaction | JANX | Common Stock | Sale | -$557K | -11K | -62.96% | $50.80 | 6.45K | Oct 16, 2024 | Direct | F6, F7 |
| transaction | JANX | Common Stock | Options Exercise | $14.2K | +836 | +12.97% | $17.00 | 7.28K | Oct 17, 2024 | Direct | F6 |
| transaction | JANX | Common Stock | Options Exercise | $3.73K | +348 | +4.78% | $10.73 | 7.63K | Oct 17, 2024 | Direct | F6 |
| transaction | JANX | Common Stock | Options Exercise | $4.6K | +348 | +4.56% | $13.22 | 7.98K | Oct 17, 2024 | Direct | F6 |
| transaction | JANX | Common Stock | Options Exercise | $9.43K | +237 | +2.97% | $39.80 | 8.21K | Oct 17, 2024 | Direct | F6 |
| transaction | JANX | Common Stock | Sale | -$92.2K | -1.84K | -22.44% | $50.02 | 6.37K | Oct 17, 2024 | Direct | F6, F8 |
| transaction | JANX | Common Stock | Sale | -$5.17M | -103K | -3.76% | $50.30 | 2.63M | Oct 18, 2024 | Direct | F2, F9 |
| transaction | JANX | Common Stock | Sale | -$1M | -19.9K | -3.76% | $50.30 | 509K | Oct 18, 2024 | By Avalon BioVentures I, LP | F3, F9 |
| transaction | JANX | Common Stock | Sale | -$5.28M | -105K | -3.76% | $50.30 | 2.68M | Oct 18, 2024 | By Avalon BioVentures SPV I, L.P. | F4, F9 |
| transaction | JANX | Common Stock | Sale | -$791K | -15.5K | -0.59% | $51.18 | 2.61M | Oct 18, 2024 | Direct | F2, F10 |
| transaction | JANX | Common Stock | Sale | -$153K | -3K | -0.59% | $51.18 | 506K | Oct 18, 2024 | By Avalon BioVentures I, LP | F3, F10 |
| transaction | JANX | Common Stock | Sale | -$808K | -15.8K | -0.59% | $51.18 | 2.67M | Oct 18, 2024 | By Avalon BioVentures SPV I, L.P. | F4, F10 |
| transaction | JANX | Common Stock | Sale | -$24.2M | -542K | -20.73% | $44.75 | 2.07M | Oct 18, 2024 | Direct | F2, F11 |
| transaction | JANX | Common Stock | Sale | -$4.7M | -105K | -20.73% | $44.75 | 401K | Oct 18, 2024 | By Avalon BioVentures I, LP | F3, F11 |
| transaction | JANX | Common Stock | Sale | -$24.8M | -553K | -20.73% | $44.75 | 2.12M | Oct 18, 2024 | By Avalon BioVentures SPV I, L.P. | F4, F11 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | JANX | Stock Option (right to buy) | Options Exercise | $0 | -4.97K | -17.91% | $0.00 | 22.8K | Oct 16, 2024 | Common Stock | 4.97K | $17.00 | Direct | F6, F12 |
| transaction | JANX | Stock Option (right to buy) | Options Exercise | $0 | -2.07K | -17.91% | $0.00 | 9.49K | Oct 16, 2024 | Common Stock | 2.07K | $10.73 | Direct | F6, F12 |
| transaction | JANX | Stock Option (right to buy) | Options Exercise | $0 | -2.07K | -17.91% | $0.00 | 9.49K | Oct 16, 2024 | Common Stock | 2.07K | $13.22 | Direct | F6, F12 |
| transaction | JANX | Stock Option (right to buy) | Options Exercise | $0 | -1.41K | -18.23% | $0.00 | 6.31K | Oct 16, 2024 | Common Stock | 1.41K | $39.80 | Direct | F6, F12 |
| transaction | JANX | Stock Option (right to buy) | Options Exercise | $0 | -836 | -3.67% | $0.00 | 21.9K | Oct 17, 2024 | Common Stock | 836 | $17.00 | Direct | F6, F12 |
| transaction | JANX | Stock Option (right to buy) | Options Exercise | $0 | -348 | -3.67% | $0.00 | 9.14K | Oct 17, 2024 | Common Stock | 348 | $10.73 | Direct | F6, F12 |
| transaction | JANX | Stock Option (right to buy) | Options Exercise | $0 | -348 | -3.67% | $0.00 | 9.14K | Oct 17, 2024 | Common Stock | 348 | $13.22 | Direct | F6, F12 |
| transaction | JANX | Stock Option (right to buy) | Options Exercise | $0 | -237 | -3.76% | $0.00 | 6.07K | Oct 17, 2024 | Common Stock | 237 | $39.80 | Direct | F6, F12 |
Avalon Ventures XI, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| F2 | The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| F3 | The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| F4 | The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| F5 | The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| F6 | The securities are directly held by Mr. Lichter. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.76 to $51.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F8 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.97 to $50.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F9 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F10 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F11 | Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024. |
| F12 | Immediately exercisable. |